These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 19947038

  • 1. Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: a report of 2 cases.
    Phippen NT, Leath CA.
    J Reprod Med; 2009 Sep; 54(9):583-6. PubMed ID: 19947038
    [Abstract] [Full Text] [Related]

  • 2. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF.
    Cancer; 2008 Jan 15; 112(2):331-9. PubMed ID: 18058810
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.
    Gynecol Oncol; 2004 Dec 15; 95(3):686-90. PubMed ID: 15581982
    [Abstract] [Full Text] [Related]

  • 4. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.
    Gynecol Oncol; 2008 Jan 15; 108(1):53-7. PubMed ID: 17904208
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, Partridge EE, Austin JM, Alvarez RD.
    Gynecol Oncol; 2007 Mar 15; 104(3):591-5. PubMed ID: 17045635
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
    Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T.
    Gynecol Oncol; 2007 Apr 15; 105(1):205-10. PubMed ID: 17239430
    [Abstract] [Full Text] [Related]

  • 7. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    O'Malley DM, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M, Schwartz P, Rutherford T.
    Gynecol Oncol; 2005 Aug 15; 98(2):242-8. PubMed ID: 15992916
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma.
    Chan JK, Manuel MR, Ciaravino G, Cheung MK, Husain A, Teng NN.
    Gynecol Oncol; 2006 Dec 15; 103(3):919-23. PubMed ID: 16828852
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
    Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D.
    Gynecol Oncol; 2011 Dec 15; 123(3):499-504. PubMed ID: 21955480
    [Abstract] [Full Text] [Related]

  • 11. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.
    Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG.
    Gynecol Oncol; 2006 Nov 15; 103(2):637-41. PubMed ID: 16781766
    [Abstract] [Full Text] [Related]

  • 12. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE.
    Gynecol Oncol; 2001 Sep 15; 82(3):420-6. PubMed ID: 11520135
    [Abstract] [Full Text] [Related]

  • 13. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
    Hanjani P, Nolte S, Shahin MS.
    Gynecol Oncol; 2002 May 15; 85(2):278-84. PubMed ID: 11972388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D.
    Cancer Chemother Pharmacol; 2007 Jun 15; 60(1):123-8. PubMed ID: 17111119
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS, Park NH, Kang S, Seo SS, Chung HH, Kim JW, Song YS, Kang SB.
    J Obstet Gynaecol Res; 2010 Feb 15; 36(1):86-93. PubMed ID: 20178532
    [Abstract] [Full Text] [Related]

  • 20. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
    Miller DS, Blessing JA, Lentz SS, McMeekin DS.
    Cancer; 2003 Oct 15; 98(8):1664-9. PubMed ID: 14534883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.